Alleviation of obesity cardiomyopathy by Fisetin through the inhibition of NF-κB/MAPK signaling
- 20 February 2025
- journal article
- Published by Elsevier in International Immunopharmacology
- Vol. 151, 114319
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82273842)
- National Natural Science Foundation of China (82073705)
- Natural Science Foundation of Zhejiang Province (LR22H300002)
- Natural Science Foundation of Zhejiang Province (LTGD23H160005)
This publication has 20 references indexed in Scilit:
- Inhibition of TAK1/TAB2 complex formation by costunolide attenuates obesity cardiomyopathy via the NF-κB signaling pathwayPhytomedicine, 2022
- Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1/MAPK signalingActa Pharmacologica Sinica, 2022
- Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical studySignal Transduction and Targeted Therapy, 2020
- Phillygenin inhibits LPS-induced activation and inflammation of LX2 cells by TLR4/MyD88/NF-κB signaling pathwayJournal of Ethnopharmacology, 2020
- Alprostadil attenuates LPS-induced cardiomyocyte injury by inhibiting the Wnt5a/JNK/NF-κB pathwayHerz, 2019
- Understanding early TLR signaling through the MyddosomeJournal of Leukocyte Biology, 2018
- Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the MyocardiumJACC, 2018
- Saturated palmitic acid induces myocardial inflammatory injuries through direct binding to TLR4 accessory protein MD2Nature Communications, 2017
- Fisetin and Its Role in Chronic Diseases2016
- Proinflammatory, anti-inflammatory cytokines and adiponkines in students with central obesityCytokine, 2013